Article Text

Download PDFPDF

Brief Report About the Role of Hyperthermic Intraperitoneal Chemotherapy in a Prospective Randomized Phase 3 Study in Recurrent Ovarian Cancer From Spiliotis et al
  1. Philipp Harter, MD, PhD,
  2. Alexander Reuss, MSc,
  3. Jalid Sehouli, MD, PhD,
  4. Luis Chiva, MD, PhD and
  5. Andreas du Bois, MD, PhD
  1. * Department of Gynecology & Gynecologic Oncology, Kliniken Essen Mitte, Essen;
  2. Coordinating Center for Clinical Trials, Philipps-University Marburg, Marburg;
  3. Department of Gynecology, Charité, Berlin, Germany; and
  4. § Department of Gynecology Oncology, MD Anderson Cancer Center, Madrid, Spain.
  1. Address correspondence and reprint requests to Philipp Harter, MD, Department of Gynecology & Gynecologic Oncology, Kliniken Essen Mitte, Henricistr 92, 45136 Essen, Germany. E-mail: p.harter{at}


Abstract A published so-called phase 3 study regarding HIPEC in ovarian cancer raised multiple questions. This commentary focusses on the weakness of the publication and discusses this in detail.

  • Ovarian cancer
  • Hyperthermic intraperitoneal chemotherapy
  • Study design

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • The authors declare no conflicts of interest.